Company intelligence / Profile preview

Adello Biologics, LLC

Piscataway, New Jersey, United Statesuspto.gov ↗

Ownership: Private
Development stage: Other

Overview

Completed Phase 1 studies for filgrastim biosimilar (referencing Neupogen®) and pegfilgrastim biosimilar (TPI-120). FDA accepted BLA for filgrastim biosimilar in September 2017. Both products were in development when the company was acquired by Kashiv Pharma in January 2019.

Therapeutic areas: ImmunologyOncology
Modalities: Biosimilarsproteinscomplex monoclonal antibodies
Industry: Biotech

Beyond the preview

Go deeper on Adello Biologics, LLC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Adello Biologics, LLC.

Explore the full profile